| Literature DB >> 22677229 |
Ryotaro Nakamura1, Joycelynne M Palmer, Margaret R O'Donnell, Tracey Stiller, Sandra H Thomas, Joseph Chao, Joseph Alvarnas, Pablo M Parker, Vinod Pullarkat, Rodrigo Maegawa, Anthony S Stein, David S Snyder, Ravi Bhatia, Karen Chang, Shirong Wang, Ji-Lian Cai, David Senitzer, Stephen J Forman.
Abstract
We report a consecutive series of 59 patients with MDS who underwent reduced-intensity hematopoietic stem cell transplantation (RI-HSCT) with fludarabine/melphalan conditioning and tacrolimus/sirolimus-based GVHD prophylaxis. Two-year OS, EFS, and relapse incidences were 75.1%, 65.2%, and 20.9%, respectively. The cumulative incidence of non-relapse mortality at 100 days, 1 year, and 2 years was 3.4%, 8.5%, and 10.5%, respectively. The incidence of grade II-IV acute GVHD was 35.4%; grade III-IV was 18.6%. Forty of 55 evaluable patients developed chronic GVHD; of these 35 were extensive grade. This RI-HSCT protocol produces encouraging outcomes in MDS patients, and tacrolimus/sirolimus-based GVHD prophylaxis may contribute to that promising result.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22677229 PMCID： PMC3433241 DOI： 10.1016/j.leukres.2012.04.022
Source DB: PubMed Journal: Leuk Res ISSN： 0145-2126 Impact factor: 3.156